Janus Kinase 1 in Vitiligo & Psoriasis

Vitiligo Clinical Trial

Official title:

Expression of Janus Kinase 1 in Vitiligo and Psoriasis Before and After Narrow Band UVB: a Case-Control Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03762551
• Other study ID #: Dermatology 11
• Status: Completed
• Phase: N/A
• Start date: December 2015
• Est. completion date: November 2016

Study information

• Verified date: November 2015
• Source: Cairo University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Assessment of the level of JAK1 in both vitiligo and psoriasis patients before and after treatment with NB-UVB which is considered a gold standard therapy for both diseases.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: November 2016
• Est. primary completion date: November 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

• age above 12 years of age.

• psoriasis vulgaris or non-segmental vitiligo

• patients who received no systemic or topical treatment at least 6 weeks prior to enrollment into the study.

Exclusion Criteria:

• psoriasis patients with erythrodermic psoriasis, pustular psoriasis or associated psoriatic arthritis

• vitiligo patients with segmental or universal vitiligo were excluded from the study.

• any patient with a photosensitive disorder or any contraindication to phototherapy exposure, e.g., history or presence of malignant or premalignant skin lesions.

Related Conditions & MeSH terms

• Psoriasis
• Vitiligo

Intervention

Other:
• skin biopsy
Two (4 mm) punch skin biopsies were taken from the 20 patients; one prior to the initiation of phototherapy and the other after the last session (from the same site). One skin biopsy was taken from the skin of each of the 10 control healthy participants. Skin biopsy specimens were preserved in Radio-Immunoprecipitation Assay (RIBA) buffer.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Cairo University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measurement of the tissue level of JAK1 in both vitiligo and psoriasis patients before and after treatment with NB-UVB		1 year